TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04259255

Intervention type: DRUG
Intervention: Edaravone (Radicava®/Radicava ORS®)
Description: Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles.
Study: NCT04375839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implant
Description: Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implant
Description: Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
Study: NCT03274713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Description: Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
Study: NCT04689100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: IV infusion Q2W (28-day cycles)
Study: NCT02459665

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence
Description: Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV

Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic use of metronidazole pills (500 mg)
Description: Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Lcr35-containing probiotic for prevention of BV recurrence
Description: Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
Study: NCT04102241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos are the same as drugs, but contain no Hemay005.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos are the same as drugs, but contain no Hemay005.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos are the same as drugs, but contain no Hemay005.
Study: NCT03712241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: Topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Capsule
Study: NCT04906317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and dezocine
Description: Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
Study: NCT00964288

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 low dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 low dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 low dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 low dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: positive control

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 high dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 high dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 high dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 high dose
Description: oral tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK drug and positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK drug and positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK drug and positive control

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK drug and positive control
Study: NCT04551820

Intervention type: PROCEDURE
Intervention: Regular Hours
Description: The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.

Intervention type: PROCEDURE
Intervention: After Hours
Description: The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.

Intervention type: DEVICE
Intervention: Robotic-assisted Cholecystectomy
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.

Intervention type: DEVICE
Intervention: Robotic-assisted Cholecystectomy
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
Study: NCT02062801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
Study: NCT01049412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2605541
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
Study: NCT05878379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Iron Program
Description: Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)
Study: NCT01820858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m(2), intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paraplatin (Carboplatin Injection)
Description: AUC=5, IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Radiation
Description: 45-50 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Brachytherapy 1
Description: 5 Gy, 3 times

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy 2
Description: 5 Gy, 2-4 times
Study: NCT01533415

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES treatment using Alpha-Stim technology
Description: Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame CES Treatment
Description: Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
Study: NCT02286063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory Oxygen
Description: The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm.
Study: NCT02996578

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low polyphenol content chocolate bar
Description: Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: low polyphenol content cocoa powder
Description: Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
Study: NCT04639167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paths to everyday life (PEER)
Description: The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
Study: NCT02938104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Isolate Powder
Description: Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Program
Description: Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD
Study: NCT01546389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
Study: NCT02938104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Techniques
Description: Relaxation techniques consisting of breathing exercises and using a relaxation CD
Study: NCT01112358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-FSH
Description: r-FSH will be administered as specified in the arm description.
Study: NCT01945424

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: No Intervention as part of this protocol
Study: NCT04116476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: Single Dose of MT-7117
Study: NCT01112358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-FSH
Description: r-FSH will be administered as specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hLH
Description: r-hLH will be administered as specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analogous GnRH antagonist
Description: Analogous GnRH antagonist will be administered as specified in the arm description.
Study: NCT01638949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.
Study: NCT04116476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: Single Dose of MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: Single Dose of MT-7117
Study: NCT01638949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.
Study: NCT02557542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Stop Vein Clinic
Description: Same day diagnosis and treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Stop Vein Clinic
Description: Same day diagnosis and treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Venous ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Venous ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation
Description: Venous ablation
Study: NCT01869751

Intervention type: DRUG
Intervention: Prucalopride
Description: Treatment with prucalopride for slow-transit constipation
Study: NCT00694954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Test - Given Imaging Pillcam
Description: Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostics
Description: Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
Study: NCT02557542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Description: Venous ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)
Description: Venous ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)
Description: Venous ablation
Study: NCT02918409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Study: NCT01404026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
Study: NCT03134651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring brain function

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring brain function
Study: NCT03637231

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultra low-dose CTAC
Description: All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
Study: NCT03309488

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral food challenge
Description: Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral food challenge
Description: Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.